RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:300865

Primary cutaneous anaplastic large cell lymphoma

low confidenceDisorder

Also known as: Primary C-ALCL · Regressive atypical histiocytosis

Publications

1,051

Trials

9

Interventional, condition-specific

Researchers

1,069

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare T-cell non-Hodgkin lymphoma that affects the skin and generally shows no extracutaneous involvement at presentation. It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders along with lymphomatoid papulosis with which it shares overlapping clinical and histopathologic features.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (10)

ALCL, cutaneous · C-ALCL · anaplastic large-cell lymphoma, primary cutaneous type · primary C-ALCL · primary anaplastic large cell lymphoma of skin · primary anaplastic large cell lymphoma of the skin · primary cutaneous CD30 Positive anaplastic large cell lymphoma · primary cutaneous CD30+ ALCL · primary cutaneous CD30+ anaplastic large cell lymphoma · regressive atypical histiocytosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,051 matched papers (665 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    9 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,051

1,051 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,051 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

665 in the last 10 years · low confidence

Phrase hits: 1,050 · MeSH hits: 1

Open Europe PMC search

Who's working on it?

1,069

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Melchers RC6 papers · 2024

    Department of Dermatology, Leiden University Medical Center, the Netherlands.

    Papers in Europe PMC
  2. 02
    Li S5 papers · 2026

    Winship Cancer Institute, Emory University, Atlanta, GA, USA.

    Papers in Europe PMC
  3. 03
    Quint KD5 papers · 2022

    Department of Dermatology, Leiden University Medical Center, the Netherlands.

    Papers in Europe PMC
  4. 04
    Vermeer MH5 papers · 2024

    Department of Dermatology, Leiden University Medical Center, the Netherlands.

    Papers in Europe PMC
  5. 05
    Chen H4 papers · 2025

    Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.

    Papers in Europe PMC
  6. 06
    Kempf W4 papers · 2025

    Kempf und Pfaltz Histologische Diagnostik, 8050 Zürich, Switzerland.

    Papers in Europe PMC
  7. 07
    Quaglino P4 papers · 2024

    Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.

    Papers in Europe PMC
  8. 08
    Willemze R4 papers · 2022

    Department of Dermatology, Leiden University Medical Center, the Netherlands.

    Papers in Europe PMC
  9. 09
    Zhang C4 papers · 2025

    Pathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanging, China, zccjy0614@163.com.

    Papers in Europe PMC
  10. 10
    Zhang Y4 papers · 2026

    Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

9

interventional trials for this specific condition

9 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 176 trials are registered for anaplastic large cell lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

9 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.2th percentile).

low confidence · 91.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

9 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: anaplastic large cell lymphoma

176

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Primary cutaneous anaplastic large cell lymphoma" OR "Primary C-ALCL" OR "Regressive atypical histiocytosis" OR "ALCL, cutaneous" OR "C-ALCL" OR "anaplastic large-cell lymphoma, primary cutaneous type" OR "primary anaplastic large cell lymphoma of skin" OR "primary anaplastic large cell lymphoma of the skin" OR "primary cutaneous CD30 Positive anaplastic large cell lymphoma" OR "primary cutaneous CD30+ ALCL" OR "primary cutaneous CD30+ anaplastic large cell lymphoma"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Lymphoma, Primary Cutaneous Anaplastic Large Cell

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Primary cutaneous anaplastic large cell lymphoma" OR "Primary C-ALCL" OR "Regressive atypical histiocytosis" OR "ALCL, cutaneous" OR "C-ALCL" OR "anaplastic large-cell lymphoma, primary cutaneous type" OR "primary anaplastic large cell lymphoma of skin" OR "primary anaplastic large cell lymphoma of the skin" OR "primary cutaneous CD30 Positive anaplastic large cell lymphoma" OR "primary cutaneous CD30+ ALCL" OR "primary cutaneous CD30+ anaplastic large cell lymphoma" OR "Lymphoma, Primary Cutaneous Anaplastic Large Cell"

Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 9 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"anaplastic large cell lymphoma"

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1051) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T12:44:37.031Z